Holen Sie sich die Stockscreener-App
24.21
3.28%
0.77
Handel nachbörslich:
24.21
Schlusskurs vom Vortag:
$23.44
Offen:
$23.69
24-Stunden-Volumen:
134.21K
Relative Volume:
0.45
Marktkapitalisierung:
$1.09B
Einnahmen:
$45.95M
Nettoeinkommen (Verlust:
$-48.88M
KGV:
-21.75
EPS:
-1.1129
Netto-Cashflow:
$109.67M
1W Leistung:
+0.41%
1M Leistung:
-19.27%
6M Leistung:
+44.54%
1J Leistung:
+296.89%
1-Tages-Spanne:
$23.50
$25.07
1-Wochen-Bereich:
$22.97
$25.33
52-Wochen-Spanne:
$4.66
$32.63
Septerna Inc Stock (SEPN) Company Profile
Firmenname
Septerna Inc
Sektor
Branche
Telefon
650-338-3533
Adresse
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
24.21 | 1.05B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-15 | Eingeleitet | Truist | Buy |
| 2025-11-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-11-19 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-19 | Eingeleitet | TD Cowen | Buy |
| 2024-11-19 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Septerna Inc Aktie (SEPN) Neueste Nachrichten
Septerna, Inc. (NASDAQ:SEPN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Septerna tops Q4 loss expectations as collaboration revenue lifts results - MSN
J.P. Morgan Maintains Septerna(SEPN.US) With Buy Rating, Announces Target Price $38 - Moomoo
Septerna (NASDAQ:SEPN) Given New $38.00 Price Target at JPMorgan Chase & Co. - MarketBeat
JP Morgan Raises Price Target for Septerna (SEPN) to $38 | SEPN Stock News - GuruFocus
Septerna price target raised to $38 from $34 at JPMorgan - TipRanks
Should Septerna’s New ATM and Shelf Offering Strategy Require Action From Septerna (SEPN) Investors? - simplywall.st
Big Picture: How volatile is Septerna Inc stock2026 WrapUp & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Septerna (SEPN) Expected to Announce Earnings on Thursday - MarketBeat
Layoff Watch: Will Septerna Inc outperform the market in YEARTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Septerna (SEPN) Is Down 13.5% After Launching US$150 Million ATM Equity Program and Filing Shelves - simplywall.st
Checkpoint Capital L.P. Trims Stock Position in Septerna, Inc. $SEPN - MarketBeat
Avoro Capital Advisors LLC Grows Stock Holdings in Septerna, Inc. $SEPN - MarketBeat
Septerna (NASDAQ:SEPN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
HC Wainwright Has Negative Outlook for Septerna Q1 Earnings - MarketBeat
What is HC Wainwright's Forecast for Septerna Q1 Earnings? - MarketBeat
Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail
Truist Financial Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock - MarketBeat
Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative - simplywall.st
Wells Fargo Reaffirms Their Buy Rating on Septerna, Inc. (SEPN) - The Globe and Mail
Truist Lifts Price Target on Septerna to $35 From $34, Keeps Buy Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on Septerna, Inc. (SEPN) March 2026 - Meyka
Truist raises Septerna stock price target to $35 on trial progress - Investing.com
Cantor Fitzgerald reiterates Septerna stock rating on platform value By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Septerna stock rating on platform value - Investing.com
Septerna (SEPN) Reports Narrower Q4 Loss of $0.24/Share as Revenue Climbs to $24.1M - AlphaStreet
Septerna beats fourth quarter loss estimates on collaboration revenue By Investing.com - Investing.com Canada
Septerna beats fourth quarter loss estimates on collaboration revenue - Investing.com
Decoding Septerna Inc (SEPN): A Strategic SWOT Insight - GuruFocus
Septerna, Inc. (SEPN) reports Q4 loss, tops revenue estimates - MSN
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates - Bitget
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24 - marketscreener.com
Biotech firm Septerna beats Q4 revenue expectations, net loss narrows - TradingView
Earnings Summary: Septerna Q4 - Benzinga
Septerna, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
SEPN: Pipeline advances and improved financials set stage for clinical milestones in 2026 - TradingView
Earnings Flash (SEPN) Septerna, Inc. Reports Q4 Revenue $24.1M, vs. FactSet Est of $18.2M - marketscreener.com
SEPN SEC FilingsSepterna, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
How Investors May Respond To Septerna (SEPN) Advancing SEP-631 Into Phase 2b Urticaria Trials - simplywall.st
Can Septerna Inc. stock hit record highs againEarnings Performance Report & Fast Exit Strategy with Risk Control - Naître et grandir
Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells 70,453 Shares of Stock - MarketBeat
Septerna (SEPN) CPO exercises options, then sells 70,453 shares - Stock Titan
Septerna Executive Sells Shares - TradingView
SEPN: SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials - TradingView
SEPN: SEP-631 and SEP-479 advance with strong data, phase 2 and 1 trials planned, and pipeline growth - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Payoneer (PAYO) and Porch Group (PRCH) - The Globe and Mail
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Sahm
A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment - Sahm
Finanzdaten der Septerna Inc-Aktie (SEPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):